Bio-Rad Laboratories filed its required 13F reports with the SEC on September 7, 2026.
1 report, 1 independent
Updated Sep 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bio-Rad Laboratories filed its required 13F reports with the SEC on September 7, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Bio-Rad Laboratories
American life science research firm
- Strategic acquisitions and product launches are driving growth for Bio-Rad Laboratories in the life science ddPCR and clinical diagnostics markets.
- Bio-Rad Laboratories is applying digital PCR technology through current partnerships, including Biodesix, Gencove, Insight Molecular, and Stilla Technologies.
-
SEC
Slovak company
Related events
- Regeneron Pharmaceuticals filed required reports with the SEC regarding institutional holdings on September 8, 2026.
- ADMA Biologics, Inc. filed its required 13F filings regarding institutional holdings with the SEC.
- CF Industries filed required 13F reports with the SEC on September 7, 2026.
- RadNet filed required reports with the SEC and traded on the Nasdaq stock exchange.
- TransMedics Group, Inc. filed required reports with the SEC on August 27, 2026.